USF Board of Trustees v. USPTO: Federal Circuit Affirms in Alzheimer’s Mouse Patent Appeal
The University of South Florida Board of Trustees challenged the USPTO before the Court of Appeals for the Federal Circuit over patent US5898094A, covering transgenic mice engineered to model Alzheimer’s disease. The Federal Circuit affirmed the USPTO’s position, closing the appeal after 504 days.
Federal Circuit closes Alzheimer’s mouse patent dispute against USPTO
The University of South Florida Board of Trustees filed this appeal at the Court of Appeals for the Federal Circuit on 23 September 2022, challenging the United States Patent and Trademark Office over the validity or enforceability of US5898094A. The patent in dispute covers transgenic mice co-expressing the APPK670N,M671L mutation and a mutant presenilin transgene — a dual-transgene model central to Alzheimer’s disease research. USF was represented by The Kelber Law Group, with attorneys Jerry Stouck and Steven B. Kelber leading the challenge.
The Federal Circuit issued its order on 9 February 2024, affirming the USPTO’s position. The basis of termination is recorded as ‘Appeal Dismissed,’ and the court’s judgment reads: ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED.’ This outcome means the USPTO’s underlying determination stands without modification, and USF’s appellate arguments were not accepted by the court. The appeal was dismissed consistent with the affirmance.
The case ran for 504 days from filing to close — a timeline consistent with contested Federal Circuit patent appeals. The public record does not disclose the precise USPTO proceeding being appealed (e.g., inter partes review, ex parte re-examination, or a PTAB decision), which limits further inference about the scope of the underlying dispute. The affirmance leaves the USPTO’s ruling intact and suggests USF was unable to overcome the administrative record on appeal.
Filing to dismissal in 504 days
504 days — full appellate lifecycle at the Federal Circuit
Federal Circuit affirmed: what the judgment means for each party
Affirmance: the USPTO’s ruling is left fully intact
When the Federal Circuit affirms, it is confirming that the lower tribunal — here the USPTO or a PTAB panel — committed no reversible error. USF’s arguments on appeal were insufficient to overturn the agency’s determination. The practical effect is that whatever the USPTO decided regarding US5898094A continues to stand as the operative legal position, with no remand or modification ordered.
USPTO determination upheldAppeal Dismissed: scope and implications for USF
The recorded basis of termination is ‘Appeal Dismissed,’ coupled with an affirmance order. This phrasing typically signals the Federal Circuit resolved the merits in the USPTO’s favour rather than dismissing on procedural grounds alone, though the public record does not specify the precise grounds. USF’s options after a Federal Circuit affirmance are limited: en banc rehearing or a petition for certiorari to the Supreme Court, both of which face high procedural bars.
Limited further appellate routesUS5898094A covers a foundational Alzheimer’s research model
US5898094A protects transgenic mice expressing both the APPK670N,M671L amyloid precursor protein mutation and a mutant presenilin transgene. This dual-transgene approach accelerates amyloid plaque formation, making these animals valuable tools for Alzheimer’s drug screening. Patent rights over such a model carry significant licensing and commercial research value, explaining why USF pursued appeal through the Federal Circuit.
Biomedical research tool patentUniversity patent rights: what a USPTO adverse ruling costs
For a public university board of trustees, losing control of a foundational research-tool patent can affect licensing revenue, sponsored research agreements, and exclusive commercialisation arrangements with biotech partners. An adverse USPTO determination — affirmed by the Federal Circuit — may restrict USF’s ability to assert, license, or monetise the patent going forward, depending on the specific claim outcome underlying the appeal.
University IP commercialisation riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | University of South Florida Board of Trustees | Company | Public research university IP holding entity — holder of US5898094ASearch in Eureka ↗ |
| Defendant | United States and Trademark Office | Company | United States Patent and Trademark Office — federal agency administering patent rightsSearch in Eureka ↗ |
| Plaintiff counsel | Jerry Stouck | Attorney | Counsel for University of South Florida Board of TrusteesSearch in Eureka ↗ |
| Plaintiff counsel | Steven B. Kelber | Attorney | Counsel for University of South Florida Board of TrusteesSearch in Eureka ↗ |
| Defendant counsel | Brian M. Boynton | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Defendant counsel | Carrie Rosato | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Defendant counsel | Gary Lee Hausken | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Defendant counsel | Kavyasri Nagumotu | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Defendant counsel | Walter W. Brown | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | Court of Appeals for the Federal Circuit — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The court’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is a merits affirmance, meaning the Federal Circuit reviewed the USPTO’s underlying determination and found no reversible error. For USF, this forecloses further challenge at this court level. For the USPTO, it validates the administrative record. The terse framing is standard Federal Circuit practice for affirmed appeals and does not necessarily indicate a Rule 36 summary affirmance versus a reasoned opinion without further detail in the available record.
US5898094A — Dual-Transgene Alzheimer’s Mouse Model
US5898094A (application number US08/903518) protects transgenic mice co-expressing the Swedish APP mutation (APPK670N,M671L) and a mutant presenilin transgene. Together these transgenes dramatically accelerate amyloid-beta plaque deposition — the hallmark pathology of Alzheimer’s disease — in living animal models. This makes the patented animals a key research tool for evaluating candidate therapeutics and disease mechanisms. The patent was filed in the 1990s during a competitive race to develop reliable Alzheimer’s animal models with predictive translational value.
Ownership of a patent on a widely-used preclinical research platform confers significant leverage: any commercial entity running Alzheimer’s drug screening programmes using these specific transgenic constructs may require a licence from the patent holder. The Federal Circuit’s affirmance of the USPTO’s ruling — whatever the specific underlying determination — introduces uncertainty for USF’s ability to enforce or license the patent and may affect existing licensing agreements. Competitors and licensees in the Alzheimer’s research space should monitor how the USPTO’s affirmed position affects the patent’s claim scope.
Should your team run an FTO analysis against US5898094A?
Any pharmaceutical, biotechnology, or contract research organisation using transgenic mouse models that co-express APP Swedish mutations and presenilin variants in Alzheimer’s research should assess freedom-to-operate against US5898094A. The patent’s scope potentially captures widely-used preclinical assay workflows. Although the USPTO’s ruling — affirmed on appeal — may limit certain claims, the boundaries of what remains enforceable are not publicly clear from this case record alone. R&D teams should not assume the case outcome resolves their FTO exposure.
PatSnap Eureka’s FTO Search Agent allows you to map your transgenic animal research workflows against the claim landscape of US5898094A and related patents in real time. Eureka can flag overlapping claims, identify design-around space, and monitor for any post-appeal prosecution activity or continuation filings that could extend the patent family’s reach. For organisations active in Alzheimer’s preclinical research, setting a claim-change alert on this family is a low-cost, high-value risk management step.
Run a freedom-to-operate analysis on US5898094A to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patent appeals involving biomedical research tools
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for biomedical research-tool patent strategy
The Federal Circuit’s affirmance reinforces how difficult it is for research universities to reverse USPTO determinations on appeal — even on high-value biomedical patents.
Federal Circuit deference to USPTO makes pre-prosecution strategy critical
This affirmance is consistent with the Federal Circuit’s well-documented tendency to defer to USPTO and PTAB determinations unless clear legal error is shown. For biomedical patent holders, it underscores that the strongest position is built during prosecution and post-grant proceedings — not at appeal.
Research-tool patents face unique validity and ownership pressures
Transgenic animal patents are subject to inventorship disputes, federally-funded invention disclosure obligations under the Bayh-Dole Act, and aggressive PTAB challenges. Universities holding such patents should audit ownership chains and government licence obligations before asserting or defending these rights in any proceeding.
University v United — key questions answered
The Court of Appeals for the Federal Circuit affirmed the USPTO’s ruling on 9 February 2024. The appeal was dismissed and the USPTO’s underlying determination regarding patent US5898094A was left intact. The case ran for 504 days from filing to close.
US5898094A covers transgenic mice co-expressing the APPK670N,M671L (Swedish) amyloid precursor protein mutation and a mutant presenilin transgene. These dual-transgene animals are used as models of Alzheimer’s disease, particularly for studying amyloid plaque formation and evaluating candidate therapeutics.
The affirmance means the USPTO’s determination regarding US5898094A stands. Depending on the specific nature of that underlying ruling — which is not fully detailed in the public appellate record — the patent’s enforceability or claim scope may be affected. Companies licensing or relying on this patent should seek updated FTO and licensing advice.
The public record identifies this as an infringement action appeal but does not specify the exact USPTO or PTAB proceeding being challenged. Universities typically appeal USPTO determinations when an adverse ruling threatens licensing revenue, patent validity, or ownership rights over commercially significant research-tool patents like this transgenic mouse model.
After a Federal Circuit affirmance, a patent holder may petition for en banc rehearing before the full Federal Circuit or seek a writ of certiorari to the US Supreme Court. Both routes face high procedural and substantive bars. No further proceedings are indicated in the public record as of the case close date.
PatSnap Eureka searches patents and litigation data to answer instantly.